招商通知： 2025年9月4-5日，第三届全球手术机器人大会 2025年7月17日， 雅培公司（Abbott, NYSE: ABT） 公布了截至6月30日的2025年第二季度财务业绩。季度营收达111.42亿美元（约合人民币 799亿 ），同比增长 7.4%；有机增长（不计汇率及结构调整）达6.9%，高于市场预期。公司继续受益于核心产品线的稳健表现，特别是在医疗器械与营养品领域。 雅培董事长兼首席执行官Robert B. Ford表示："我们再次交出了一份强劲的成绩单，多个业务实现两位数增长。我们对全年业绩增长充满信心，并继续加大在创新产品 和高增长市场的投入。" # 财 报 亮 点 ： 多 项 核 心指 标 稳 中 向 好 | | | | | Established | | | --- | --- | --- | --- | --- | --- | | Sales 2Q25 ($ in millions) | Total Company | Nutrition | Diagnostics | Pharmaceuticals | Medical Devices | | U.S. | 4,276 | 957 | ...

Core Insights - Abbott Laboratories (ABT) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, beating the Zacks Consensus Estimate by 0.8% and improving 10.5% year over year [2][8] - Despite strong earnings and revenue results, ABT stock fell 5% in pre-market trading due to cautious third-quarter guidance [2][8] Revenue Performance - Worldwide sales reached $11.14 billion, a 7.4% increase year over year, surpassing the Zacks Consensus Estimate by 0.6% [3][8] - Organic sales improved by 6.9% year over year, with organic sales excluding COVID-19 rising by 7.5% [3] Segment Analysis - Established Pharmaceuticals segment sales increased by 6.9% on a reported basis to $1.38 billion, with organic sales in emerging markets growing by 8.7% [4] - Medical Devices segment sales rose 13.4% year over year to $5.37 billion, driven by Diabetes Care and Structural Heart products [5][8] - Diabetes Care division reported organic sales growth of 19.6%, with continuous glucose monitors contributing $1.90 billion to total sales [6] - Nutrition sales rose 2.9% year over year to $2.21 billion, with Adult Nutrition benefiting from strong global growth [7] - Diagnostics sales declined 1% year over year to $2.17 billion, impacted by lower COVID-19 testing-related sales [9] Margin and Expense Details - Gross profit increased by 8.9% year over year to $6.29 billion, with gross margin expanding by 79 basis points to 56.4% [9][10] - Selling, general and administration expenses rose 5.3% to $3.09 billion, while research and development expenses increased by 3.9% to $725 million [10] Financial Guidance - For full-year 2025, Abbott expects adjusted diluted EPS in the range of $5.10-$5.20, with organic sales growth projected at 7.5-8.0% [11] - Third-quarter adjusted diluted EPS is expected to be between $1.28 and $1.32, slightly below the Zacks Consensus Estimate of $1.34 [12] Strategic Developments - Abbott announced favorable data from the AVEIR Conduction System Pacing clinical study and received FDA approval for its Tendyne transcatheter mitral valve replacement system [14] - Plans to develop a new cardiovascular device manufacturing facility in Georgia, expected to be completed by 2028 [14]

Financial Performance - Abbott's worldwide sales reached $11.1 billion, reflecting a 7.5% increase[3] - Organic sales growth, excluding foreign exchange and the discontinued ZonePerfect product line, showed a growth between 7.5% to 8.0%[3, 6] - Adjusted diluted EPS was $1.26 for the quarter[4] - Full-year 2025 guidance for adjusted diluted EPS is projected to be between $5.10 and $5.20[5] Business Unit Performance - Medical Devices sales amounted to $5.4 billion[4] - Diagnostics sales reached $2.2 billion[4] - Established Pharmaceuticals sales were $1.4 billion[4] Strategic Highlights - The company is expanding its structural heart portfolio[4] - The company is pioneering leadless cardiac pacing[5] - The company is advancing heart rhythm management[7] - FDA approved Abbott's Tendyne™ transcatheter mitral valve replacement (TMVR) system[11] - The AVEIR™ Conduction System Pacing clinical feasibility study is evaluating a leadless pacemaker delivering conduction pacing[12]

Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, ...

Core Insights - Abbott Laboratories (ABT) is expected to report second-quarter 2025 results on July 17, with adjusted earnings per share (EPS) of $1.09 in the last quarter, surpassing the Zacks Consensus Estimate by 1.9% [1] - The Zacks Consensus Estimate for revenues is $11.07 billion, indicating a 6.7% increase year-over-year, while EPS is estimated to rise 9.6% to $1.25 [1][2] Revenue Estimates by Segment - **Diagnostics**: Expected revenue growth impacted by a decline in COVID-19 testing revenues, but anticipated to benefit from high demand across various settings. Estimated revenue increase of 0.1% year-over-year [3][4][6] - **Established Pharmaceuticals (EPD)**: Projected to continue strong performance across multiple regions and therapeutic areas, with a year-over-year revenue increase of 6.1% [7][8] - **Medical Devices**: Anticipated to show significant growth, driven by the Diabetes Care division and continuous glucose monitor (CGM) systems, with a projected revenue increase of 10.9% year-over-year [8][9][13] - **Nutrition**: Expected robust sales from adult nutrition brand Ensure and solid growth in infant formula and toddler brands, with a year-over-year revenue improvement of 4.3% [13] Earnings Estimate Revision - Estimates for Q2 earnings have remained unchanged at $1.25 per share over the past 30 days, indicating stability in expectations [3] Market Position and Growth Drivers - The Medical Devices segment is highlighted as a standout performer, with growth driven by new product approvals and strong demand in various categories, including heart assist devices and structural heart products [10][11][12]

Policy and Regulations - The Ministry of Commerce has announced the organization of the 2025 New Energy Vehicle Consumption Season, encouraging local participation and infrastructure development for electric vehicles [6][7][8] - Six departments proposed to reduce penalties for early loan settlements during vehicle trade-ins, aiming to stimulate car sales [9][10] - The Ministry of Industry and Information Technology has initiated a safety inspection for new energy vehicles, focusing on product quality and safety systems [11][12] Market Insights - In Mexico, from January to May 2025, pickup truck sales reached 97,000 units, marking a year-on-year increase of 4.9% [15][16] - The demand for Mexican pickups is primarily for gasoline, two-wheel drive, double cab, manual transmission, and five-seat configurations [19][21] - Japanese and American brands dominate the Mexican pickup market, with significant growth from Chinese brands [23][24] Company Monitoring - Great Wall Motors launched the G1050 hybrid flagship truck, featuring advanced hybrid technology and a price range of 536,600 to 616,600 CNY [28][30] - Changan's V919 model was officially launched, with a price range of 89,900 to 225,900 CNY, targeting both freight and passenger markets [31][32] - Remote New Energy introduced the X7E+X3E pure electric mother vehicle, emphasizing lightweight design and efficient energy use [35][36]

Core Insights - Abbott announced late-breaking data from the AVEIR Conduction System Pacing (CSP) acute clinical feasibility study, demonstrating the safety and performance of its leadless pacemaker technology [1][4] - The study is the first to assess a leadless pacemaker delivering conduction pacing to the heart's left bundle branch area, offering a novel approach to pacing therapy [1][4] Clinical Study Results - The AVEIR CSP acute clinical feasibility study showed successful implantation of the leadless pacemaker deep into the wall separating the left and right chambers of the heart, with many participants achieving left bundle branch area pacing [3] - All study participants received the AVEIR ventricular leadless pacemaker at the end of the procedure [3] Future Developments - Abbott has begun enrolling patients in the ASCEND CSP pivotal clinical trial, which will evaluate the safety and effectiveness of the investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead [6] - The trial aims to enroll up to 414 people at 70 sites worldwide, focusing on reducing complications and improving long-term outcomes for patients requiring ICD therapy [6] Regulatory Milestones - Abbott's UltiPace Pacing Lead is the first FDA-approved stylet-driven lead for left bundle branch area placement [7] - The FDA granted Breakthrough Device Designations to both the AVEIR CSP leadless pacemaker system and the CSP ICD lead for left bundle branch area pacing, expediting the review of these innovative technologies [7] Strategic Focus - Abbott is developing two unique approaches to conduction system pacing, targeting the left bundle branch area with both traditional and leadless technology [5] - The ongoing innovation in conduction system pacing is expected to drive advancements in treatment options for patients with slow or irregular heart rhythms [8]

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月16日，雅培公司（Abbott，纽约证券交易所代码：ABT）报告称，其第一季度的业绩超过了华尔街分析师对盈利的共识预期，但收入未达预期。 随后雅培的股价在早间交易中上涨了5%，达到每股132.53美元。标普500指数则略有下跌。 公布最新财报的同时，雅培宣布将在美国开展新的价值5亿美元（约合人民币36.5亿）的投资，研发制造用于筛查血液和血浆捐献的设备。 预计到2025年底 将投入使用。 # 财报亮点 数据概览 剔除汇率波动及新冠检测业务下滑影响后，雅培2025年一季度全球销售额为 103.6亿美元。 第一季度每股摊薄收益为 0.76美元 ；调整后的每股摊薄收益为1.09美元。 第一季度报告的销售额增长为 4.0% ；有机销售额增长为6.9%，若剔除与COVID-19检测相关的销售额，则增长率为8.3%。 报告的毛利率为销售额的 52.8% ；调整后的毛利率为57.1%。 报告营业利润率为销售额的 16.3% ；调整后的营业利润率为21.0%。 2025年全年指引 Abbott ...